Pleiotropic effects of fenretinide in neuroblastoma cell lines and multicellular tumor spheroids

International Journal of Oncology

Volumn 32, Issue 5, 2008, Pages 1011-1019

  Cuperus, Roos ^a   Tytgat, Godelieve A M ^a,b   Leen, René ^a   Brites, Pedro ^a   Bras, Johannes ^a   Caron, Huib N ^a   Van Kuilenburg, André B P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ZAANS MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; Fenretinide; Mitochondrial membrane potential; Neuroblastoma; Oxidative stress; Spheroids

Indexed keywords

FENRETINIDE; KI 67 ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; REACTIVE OXYGEN METABOLITE; TROLOX C; 6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-2-CARBOXYLIC ACID; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CHROMAN DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL AGGREGATION; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; DRUG CYTOTOXICITY; DRUG INDICATION; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; INCUBATION TIME; MICROMETASTASIS; MITOCHONDRIAL MEMBRANE POTENTIAL; MULTICELLULAR SPHEROID; NEUROBLASTOMA CELL; PLEIOTROPY; PRIORITY JOURNAL; TUMOR SPHEROID; ANIMAL; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEUROBLASTOMA; ONCOGENE MYC; PATHOLOGY; TIME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; CELL AGGREGATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMANS; DOSE-RESPONSE RELATIONSHIP, DRUG; FENRETINIDE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; MEMBRANE POTENTIAL, MITOCHONDRIAL; NEUROBLASTOMA; REACTIVE OXYGEN SPECIES; SPHEROIDS, CELLULAR; TIME FACTORS;

EID: 45849090770     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.32.5.1011     Document Type: Article

References (41)

1. Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313: 1111-1116, 1985.
2. Brodeur GM, Seeger RC, Sather H, et al: Clinical implications of oncogene activation in human neuroblastomas. Cancer 58: 541-545, 1986.
3. Bagatell R, Rumcheva P, London WB, et al: Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. J Clin Oncol 23: 8819-8827, 2005.
4. Abemayor E and Sidell N: Human neuroblastoma cell lines as models for the in vitro study of neoplastic and neuronal cell differentiation. Environ Health Perspect 80: 3-15, 1989.
5. Villablanca JG, Khan AA, Avramis VI, et al: Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 13: 894-901, 1995.
6. Matthay KK, Villablanca JG, Seeger RC, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341: 1165-1173, 1999.
7. Lasorella A, Iavarone A and Israel MA: Differentiation of neuroblastoma enhances Bcl-2 expression and induces alterations of apoptosis and drug resistance. Cancer Res 55: 4711-4716, 1995.
8. Delia D, Aiello A, Lombardi L, et al: N-(4-hydroxyphenyl) retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 53: 6036-6041, 1993.
9. Mariotti A, Marcora E, Bunone G, et al: N-(4-hydroxyphenyl)retinamide: a potent inducer of apoptosis in human neuroblastoma cells. J Natl Cancer Inst 86: 1245-1247, 1994.
10. Oridate N, Lotan D, Mitchell MF, Hong WK and Lotan R: Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids: implications for chemoprevention. J Cell Biochem (Suppl) 23: 80-86, 1995.
11. Hsieh TC, Ng C and Wu JM: The synthetic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR) exerts antiproliferative and apoptosis-inducing effects in the androgen-independent human prostatic JCA-1 cells. Biochem Mol Biol Int 37: 499-506, 1995.
12. Clifford JL, Menter DG, Wang M, Lotan R and Lippman SM: Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res 59: 14-18, 1999.
13. Fanjul AN, Delia D, Pierotti MA, Rideout D, Yu JQ and Pfahl M: 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem 271: 22441-22446, 1996.
14. Sun SY, Li W, Yue P, Lippman SM, Hong WK and Lotan R: Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res 59: 2493-2498, 1999.
15. Lovat PE, Oliverio S, Corazzari M, et al: Bak: a downstream mediator of fenretinide-induced apoptosis of SH-SY5Y neuroblastoma cells. Cancer Res 63: 7310-7313, 2003.
16. WF Holmes, Soprano DR and Soprano KJ: Comparison of the mechanism of induction of apoptosis in ovarian carcinoma cells by the conformationally restricted synthetic retinoids CD437 and 4-HPR. J Cell Biochem 89: 262-278, 2003.
17. Lovat PE, Ranalli M, Annichiarrico-Petruzzelli M, et al: Effector mechanisms of fenretinide-induced apoptosis in neuroblastoma. Exp Cell Res 260: 50-60, 2000.
18. West GW, Weichselbaum R and Little JB: Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res 40: 3665-3668, 1980.
19. Walker KA, Mairs R, Murray T, et al: Tumor spheroid model for the biologically targeted radiotherapy of neuroblastoma micrometastases. Cancer Res 50: S1000-S1002, 1990.
20. Smith PK, Krohn RI, Hermanson GT, et al: Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85, 1985.
21. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
22. Salinovich O and Montelaro RC: Reversible staining and peptide mapping of proteins transferred to nitrocellulose after separation by sodium dodecylsulfate-polyacrylamide gel electrophoresis. Anal Biochem 156: 341-347, 1986.
23. De Ruijter AJ, Kemp S, Kramer G, et al: The novel histone deacetylase inhibitor BL1521 inhibits proliferation and induces apoptosis in neuroblastoma cells. Biochem Pharmacol 68: 1279-1288, 2004.
24. Torrisi R and Decensi A: Fenretinide and cancer prevention. Curr Oncol Rep 2: 263-270, 2000,
25. Garaventa A, Luksch R, Lo Piccolo MS, et al: Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 9: 2032-2039, 2003.
26. Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH and Reynolds PC: Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol 24: 3423-3430, 2006.
27. Reynolds CP, Wang Y, Melton LJ, Einhorn PA, Slamon DJ and Maurer BJ: Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide. Med Pediatr Oncol 35: 597-602, 2000.
28. Wei JS, Whiteford CC, Cenacchi N, Son CG and Khan J: BBC3 mediates fenretinide-induced cell death in neuroblastoma. Oncogene 24: 7676-7683, 2005.
29. Villani MG, Appierto V, Cavadini E, et al: 4-Axo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines. Cancer Res 66: 3238-3247, 2006.
30. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC and Reynolds CP: Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines. J Natl Cancer Inst 91: 1138-1146, 1999.
31. Goto H, Takahashi H, Fujii H, Ikuta K and Yokota S: N-(4-Hydroxyphenyl)retinamide (4-HPR) induces leukemia cell death via generation of reactive oxygen species. Int J Hematol 78: 219-225, 2003.
32. Suzuki S, Higuchi M, Proske RJ, Oridate N, Hong WK and Lotan R: Implication of mitochondria-derived reactive oxygen species, cytochrome C and caspase-3 in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. Oncogene 18: 6380-6387, 1999.
33. Hewson QD, Lovat PE, Corazzari M, Catterall JB and Redfern CP: The NF-kappaB pathway mediates fenretinide-induced apoptosis in SH-SY5Y neuroblastoma cells. Apoptosis 10: 493-498, 2005.
34. Osone S, Hosoi H, Kuwahara Y, Matsumoto Y, Iehara T and Sugimoto T: Fenretinide induces sustained-activation of JNK/p38 MAPK and apoptosis in a reactive oxygen species-dependent manner in neuroblastoma cells. Int J Cancer 112: 219-224, 2004.
35. Lovat PE, Ranalli M, Corazzari M, et al: Mechanisms of free-radical induction in relation to fertretinide-induced apoptosis of neuroblastoma. J Cell Biochem 89: 698-708, 2003.
36. Lovat, PE Di Sano F, Corazzari M, et al: Gangliosides link the acidic sphingomyelinase-mediated induction of ceramide to 12-lipoxygenase-dependent apoptosis of neuroblastoma in response to fenretinide. J Natl Cancer Inst 96: 1288-1299, 2004.
37. Corazzari M, Lovat PE, Oliverio S, et al: Fenretinide: a p53-independent way to kill cancer cells. Biochem Biophys Res Commun 331: 810-815, 2005.
38. Marengo B, Raffaghello L, Pistoia V, et al: Reactive oxygen species: biological stimuli of neuroblastoma cell response. Cancer Lett 228:111-116, 2005.
39. Myatt SS, Redfern CP and Burchill SA: p38MAPK-dependent sensitivity of Ewing's sarcoma family of tumors to fenretinide-induced cell death. Clin Cancer Res 11: 3136-3148, 2005.
40. Ribatti D, Raffaghello L, Marimpietri D, et al: Fenretinide as an anti-angiogenic agent in neuroblastoma. Cancer Lett 197: 181-184, 2003.
41. Ferrari N, Pfeffer U, Dell'Eva R, Ambrosini C, Noonan DM and Albini A: The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxy-phenyl)retinamide. Clin Cancer Res 11: 4610-4619, 2005.